Treatment resistance remains a major challenge in the management of metastatic hormone-dependent breast cancer. Despite the initial effectiveness of chemotherapies, most patients eventually develop resistance, limiting therapeutic options and leading to disease progression. An innovative strategy, called an “evolutionary trap,” could change the game by exploiting the vulnerabilities acquired by cancer cells as they adapt to an initial treatment.<\/p>\n
The idea is simple: when a cancer cell becomes resistant to chemotherapy, this resistance mechanism can make it more vulnerable to a second treatment. Researchers tested this hypothesis by combining a standard chemotherapy with disulfiram, a drug already used to treat alcoholism. Known for its potential anticancer effects, disulfiram has shown the ability to specifically target resistant cells while preserving the effectiveness of the initial treatment.<\/p>\n
To validate this approach, three-dimensional cell models were used, replicating the complex environment of tumors. The results reveal that disulfiram significantly reduces the growth of resistant cells, especially when administered simultaneously with chemotherapy. Unlike sequential administration, this simultaneous combination maximizes the therapeutic effect and limits the emergence of new resistances.<\/p>\n
The underlying mechanisms were analyzed using mathematical models inspired by evolutionary game theory. These tools make it possible to predict how populations of sensitive and resistant cells interact and evolve under the influence of treatments. The data confirm that disulfiram weakens resistant cells, making them sensitive again to chemotherapy. Furthermore, this synergy between the two drugs persists even after resistance has developed, offering a sustainable solution.<\/p>\n
This study paves the way for a new strategy to extend the effectiveness of treatments for metastatic breast cancer. By exploiting the weaknesses induced by resistance, it becomes possible to design more robust and tailored therapeutic protocols. Disulfiram, already approved for other uses, could thus find a second life in oncology, reducing the costs and timelines associated with the development of new drugs.<\/p>\n
The next steps will involve refining dosages and evaluating this approach in clinical trials to confirm its potential for patients facing resistant cancers.<\/p>\n
DOI:<\/strong> https:\/\/doi.org\/10.1038\/s44320-026-00191-z<\/a><\/p>\n Title:<\/strong> A novel combination therapy for ER+ breast cancer suppresses drug resistance via an evolutionary double-bind<\/p>\n Journal:<\/strong> Molecular Systems Biology<\/p>\n Publisher:<\/strong> Springer Science and Business Media LLC<\/p>\n Authors:<\/strong> Rena Emond; Jeffrey West; Vince K Grolmusz; Patrick A Cosgrove; Aritro Nath; Alexander R A Anderson; Andrea H Bild<\/p>\n","protected":false},"excerpt":{"rendered":" Could a New Therapeutic Approach Overcome Chemotherapy Resistance in Hormone-Dependent Breast Cancer? Treatment resistance remains a major challenge in the management of metastatic hormone-dependent breast cancer. Despite the initial effectiveness of chemotherapies, most patients eventually develop resistance, limiting therapeutic options and leading to disease progression. An innovative strategy, called an “evolutionary trap,” could change the… Continue reading Could a New Therapeutic Approach Overcome Chemotherapy Resistance in Hormone-Dependent Breast Cancer?<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[6,2],"tags":[],"class_list":["post-45","post","type-post","status-publish","format-standard","hentry","category-environment","category-health","entry"],"_links":{"self":[{"href":"https:\/\/themedicinereview.com\/en\/wp-json\/wp\/v2\/posts\/45","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/themedicinereview.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/themedicinereview.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/themedicinereview.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/themedicinereview.com\/en\/wp-json\/wp\/v2\/comments?post=45"}],"version-history":[{"count":1,"href":"https:\/\/themedicinereview.com\/en\/wp-json\/wp\/v2\/posts\/45\/revisions"}],"predecessor-version":[{"id":46,"href":"https:\/\/themedicinereview.com\/en\/wp-json\/wp\/v2\/posts\/45\/revisions\/46"}],"wp:attachment":[{"href":"https:\/\/themedicinereview.com\/en\/wp-json\/wp\/v2\/media?parent=45"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/themedicinereview.com\/en\/wp-json\/wp\/v2\/categories?post=45"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/themedicinereview.com\/en\/wp-json\/wp\/v2\/tags?post=45"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}